Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
up to,19348473,absolute bioavailability,"The lead compound, 2-Me-5-thiazole-Ser(OMe)-Ser(OMe)-Phe-ketoepoxide (58) (PR-047), selectively inhibited CT-L activity of both the constitutive proteasome (beta5) and immunoproteasome (LMP7) and demonstrated an absolute bioavailability of up to 39% in rodents and dogs.",Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19348473/),%,39,1420,DB08889,Carfilzomib
,27925676,area under the concentration-time curve,"Despite inclusion of different populations (relapsed or relapsed/refractory), treatments (carfilzomib monotherapy or combination therapy), infusion lengths (2 to 10 minutes or 30 minutes), and different doses, the E-R analysis of efficacy showed that after adjusting for baseline characteristics, higher area under the concentration-time curve was associated with improved overall response rate (ORR), from 15 to 20/56 mg/m2 .",Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27925676/),[mg] / [m2],15 to 20/56,40284,DB08889,Carfilzomib
,27925676,overall response rate (ORR),"Despite inclusion of different populations (relapsed or relapsed/refractory), treatments (carfilzomib monotherapy or combination therapy), infusion lengths (2 to 10 minutes or 30 minutes), and different doses, the E-R analysis of efficacy showed that after adjusting for baseline characteristics, higher area under the concentration-time curve was associated with improved overall response rate (ORR), from 15 to 20/56 mg/m2 .",Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27925676/),[mg] / [m2],15 to 20/56,40285,DB08889,Carfilzomib
,33735504,overall response rate,"With a median follow-up of 26.7 months, in this heavily pretreated population with a median of 3 prior lines (refractory to PIs and immunomodulatory drugs, 76%; refractory to K, 27%), the overall response rate was 70% (stringent complete response/complete response, 4; very good partial response, 8; partial response, 11).","Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735504/),%,70,44482,DB08889,Carfilzomib
,33735504,progression-free survival,"The median progression-free survival was 10.1 months, and the 2-year survival probability was 76%.","Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735504/),month,10.1,44483,DB08889,Carfilzomib
,33735504,progression-free survival,"Seventy percent of the subjects responded to therapy, and the progression-free survival was 10.1 months.","Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735504/),month,10.1,44484,DB08889,Carfilzomib
,32078124,durations,"In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively.",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),,4.3,58493,DB08889,Carfilzomib
,32078124,durations,"In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively.",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),,3.4,58494,DB08889,Carfilzomib
,32078124,Kd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],254.9,58495,DB08889,Carfilzomib
,32078124,D-KRd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],277.2,58496,DB08889,Carfilzomib
,32078124,D-KRd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],256.8,58497,DB08889,Carfilzomib
,32078124,D-Kd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],319.2,58498,DB08889,Carfilzomib
,32078124,D-KRd,"At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],575.1,58499,DB08889,Carfilzomib
,32078124,D-KRd,"At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],639.2,58500,DB08889,Carfilzomib
,32078124,D-Kd,"At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],463.2,58501,DB08889,Carfilzomib
,30058108,overall response rate,"The overall response rate was 83.3% (95% confidence interval, 43.6-97.0).",Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30058108/),%,83.3,80520,DB08889,Carfilzomib
,25225420,MTD,The MTD was 56 mg/m(2).,Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25225420/),[mg] / [m(2],56,86747,DB08889,Carfilzomib
,25225420,Overall response rate (ORR),Overall response rate (ORR) was 50% (56-mg/m(2) cohort).,Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25225420/),%,50,86748,DB08889,Carfilzomib
,25225420,half-life,"Increasing carfilzomib dosing from 20 to 56 mg/m(2) resulted in higher area under the plasma concentration-time curve from time zero to last sampling and maximum plasma concentration exposure with short half-life (range, 0.837 to 1.21 hours) and dose-dependent inhibition of proteasome chymotrypsin-like activity.",Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25225420/),h,0.837 to 1.21,86749,DB08889,Carfilzomib
<,23975329,half-life,Carfilzomib PK was dose proportional with a half-life <1 h.,A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23975329/),h,1,103243,DB08889,Carfilzomib
,26924128,MTD,"In the QD and split-dose groups, the MTD was 150 and 180 mg, respectively.",A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26924128/),mg,150,118305,DB08889,Carfilzomib
,26924128,MTD,"In the QD and split-dose groups, the MTD was 150 and 180 mg, respectively.",A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26924128/),mg,180,118306,DB08889,Carfilzomib
,24904120,MTD,The MTD was determined to be 2.97 mg/m(2).,Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24904120/),[mg] / [m(2],2.97,128549,DB08889,Carfilzomib
,24904120,terminal half-life,"Pharmacokinetic studies suggested a long terminal half-life of 3.6 to 11.3 days, supporting once-weekly dosing.",Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24904120/),d,3.6 to 11.3,128550,DB08889,Carfilzomib
,21752943,plasma clearance,"Carfilzomib displayed high plasma clearance [195-319 ml/(min · kg)], a short-terminal half-life (5-20 min), and rapid and wide tissue distribution in rats.","Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21752943/),[ml] / [kg·min],195-319,145429,DB08889,Carfilzomib
,21752943,terminal half-life,"Carfilzomib displayed high plasma clearance [195-319 ml/(min · kg)], a short-terminal half-life (5-20 min), and rapid and wide tissue distribution in rats.","Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21752943/),min,5-20,145430,DB08889,Carfilzomib
,28424963,Overall response rate,Overall response rate was 43% for the normal renal function and 60% for the ESRD groups.,"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28424963/),%,43,154389,DB08889,Carfilzomib
,28424963,Overall response rate,Overall response rate was 43% for the normal renal function and 60% for the ESRD groups.,"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28424963/),%,60,154390,DB08889,Carfilzomib
less,22761464,elimination half-life,Carfilzomib was cleared rapidly with an elimination half-life of less than 30 minutes but still induced dose-dependent inhibition of the 20S chymotrypsin-like proteasome activity.,A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22761464/),min,30,200765,DB08889,Carfilzomib
,28918323,flow rate,The mobile phase consisted of 0.1% formic acid in acetonitrile -0.1% formic acid in water (1:1v/v) and the flow rate was 0.3mL/min.,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),[ml] / [min],0.3,227020,DB08889,Carfilzomib
,28918323,total chromatographic run time,The total chromatographic run time was 2.5min.,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),min,2.5,227021,DB08889,Carfilzomib
,28918323,m/z,Detection was performed on a triple quadrupole mass spectrometer equipped with positive-ion electrospray ionization by selected reaction monitoring of the transitions at m/z 720.20>100.15 (for carfilzomib) and m/z 277.05>111.05 (for the internal standard).,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),,720.20,227022,DB08889,Carfilzomib
>,28918323,m/z,Detection was performed on a triple quadrupole mass spectrometer equipped with positive-ion electrospray ionization by selected reaction monitoring of the transitions at m/z 720.20>100.15 (for carfilzomib) and m/z 277.05>111.05 (for the internal standard).,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),,100.15,227023,DB08889,Carfilzomib
>,28918323,m/z,Detection was performed on a triple quadrupole mass spectrometer equipped with positive-ion electrospray ionization by selected reaction monitoring of the transitions at m/z 720.20>100.15 (for carfilzomib) and m/z 277.05>111.05 (for the internal standard).,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),,277.05,227024,DB08889,Carfilzomib
>,28918323,m/z,Detection was performed on a triple quadrupole mass spectrometer equipped with positive-ion electrospray ionization by selected reaction monitoring of the transitions at m/z 720.20>100.15 (for carfilzomib) and m/z 277.05>111.05 (for the internal standard).,Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28918323/),,111.05,227025,DB08889,Carfilzomib
,24920586,maximum tolerated dose,"The maximum tolerated dose was 2.0 mg/m(2), which 40 patients received in 4 expansion cohorts.","Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),[mg] / [m(2],2.0,242784,DB08889,Carfilzomib
,24920586,terminal half-life,The terminal half-life of ixazomib was 3.3 to 7.4 days; plasma exposure increased proportionally with dose (0.48-2.23 mg/m(2)).,"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),d,3.3 to 7.4,242785,DB08889,Carfilzomib
,23364621,overall response rate,"Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response.",Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364621/),,25.5,248829,DB08889,Carfilzomib
,28092421,overall response rate,The overall response rate was 88.5%.,"Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092421/),%,88.5,271881,DB08889,Carfilzomib
